First Financial Corp Gilead Sciences, Inc. Transaction History

First Financial Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 11, 2023	BUY	$73.94 - $80.67 $48,430 - $52,838	655 New	655 $49,000
Q4 2020 Jan 15, 2021	SELL	$56.65 - $64.55 $14,162 - $16,137	-250 Closed	0 $0
Q3 2020 Oct 13, 2020	BUY	$62.1 - $78.08 $15,525 - $19,520	250 New	250 $16,000
Q1 2020 Apr 15, 2020	SELL	$62.63 - $80.22 $33,882 - $43,399	-541 Closed	0 $0
Q3 2019 Oct 15, 2019	BUY	$62.51 - $69.0 $25,066 - $27,669	401 Added 286.43%	541 $34,000
Q1 2018 Apr 17, 2018	SELL	$72.84 - $88.8 $3,277 - $3,996	-45 Reduced 24.32%	140 $11,000
Q4 2017 Jan 16, 2018	SELL	$71.15 - $83.52 $13,731 - $16,119	-193 Reduced 51.06%	185 $13,000
Q3 2017 Oct 13, 2017	BUY	$72.11 - $85.47 $27,257 - $32,307	378	378 $31,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of First Financial Corp , based on Form 13F filings with the SEC.

Stay updated on First Financial Corp with notifications on news.